Upcoming US Clinical Trial to Test a Tiny Eye Implant that Could Restore Sight for Age-Related Macular Degeneration (AMD)

Why It Matters

If successful, the therapy could become the first regenerative treatment to reverse vision loss in dry AMD, opening a multi‑billion‑dollar market and shifting the therapeutic paradigm from disease‑modifying to restorative.

Key Takeaways

• Phase 2b trial evaluates stem‑cell retinal implant
• Targets advanced dry AMD with geographic atrophy
• 24 participants across five U.S. sites, masked design
• Earlier study showed 27% vision improvement, good safety
• Funding from CIRM, Marcus Foundation, and USC

Pulse Analysis

Age‑related macular degeneration remains the leading cause of central vision loss among Americans over 65, affecting roughly 20 million people. While anti‑VEGF injections have transformed care for the wet form, the dry variant—particularly geographic atrophy—has few options beyond lifestyle measures. The unmet clinical need has spurred interest in cell‑based therapies that can replace the damaged retinal pigment epithelium. In this environment, USC’s phase 2b trial represents one of the most advanced attempts to move a laboratory‑grown RPE patch into routine ophthalmic practice.

The investigational device, manufactured by Regenerative Patch Technologies, consists of an ultra‑thin scaffold seeded with embryonic‑stem‑cell‑derived RPE cells. During an outpatient procedure, surgeons insert the patch beneath the retina, allowing the cells to integrate and assume the metabolic functions lost to disease. The study enrolls 24 participants across five sites in California, Illinois and Texas, employing a masked, sham‑implant control to isolate true efficacy signals. A one‑year follow‑up will capture safety, cell survival, and changes in best‑corrected visual acuity, building on a pilot that reported 27 % of subjects with measurable vision gains.

Success could unlock a new therapeutic class for dry AMD, a market projected to exceed $5 billion globally as the population ages. A positive outcome would also provide a regulatory precedent for sub‑retinal stem‑cell products, accelerating pipelines at companies such as Lineage Cell and jCyte. Investors are watching the trial closely, given its blend of academic expertise and commercial backing. Beyond financial stakes, a viable regenerative implant would shift the treatment paradigm from slowing degeneration to restoring sight, delivering tangible quality‑of‑life improvements for millions of patients.